var data={"title":"Nilotinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nilotinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/337750?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nilotinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nilotinib: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50889225\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nilotinib Treatment Discontinuation</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA has updated the product label for Novartis' <b>Tasigna</b> (nilotinib) oral capsules to include information on how to discontinue the drug in certain patients. Nilotinib is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). With the updated dosing recommendations, patients with early, chronic phase CML who have been taking nilotinib for 3 years or more, and who achieved and maintained a molecular response to treatment, may be eligible to stop taking nilotinib. The FDA has authorized specific tests to determine if patients are eligible for treatment discontinuation (see full prescribing information for details). If treatment is discontinued, patients must be regularly monitored for disease recurrence.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">More information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590391.htm?utm_campaign=12222017_PR_FDA%20updates%20label%20of%20Tasigna&utm_medium=email&utm_source=Eloqua&amp;token=+CmEuYRYpFDz/HeIs9EddroNLwaIuoO3wKjpXcUa03k/461i74iREfLReGBgWosceL9mmaDdyXiHVBkUbKumyD/fMcFSY+JHKQiqVW3IumvsylR+W7K2ng3EanM+fWfhjMyWBSqS1Rg1JcFNJV4AjoD/xbn3cC59BaNmv85zm8/RB2gAdNZ2oYNcFtwDuF95ixLwNmZucsDDtCWJksRURg==&amp;TOPIC_ID=9448\" target=\"_blank\">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590391.htm?utm_campaign=12222017_PR_FDA%20updates%20label%20of%20Tasigna&amp;utm_medium=email&amp;utm_source=Eloqua</a></p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709171\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">QT Prolongation and Sudden Deaths: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib prolongs the QT interval. Prior to nilotinib administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. Obtain electrocardiograms (ECGs) to monitor the QTc at baseline, 7 days after initiation, and periodically thereafter, and following any dose adjustments. Sudden deaths have been reported in patients receiving nilotinib. Do not use nilotinib in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors. Patient should avoid food 2 hours before and 1 hour after taking a nilotinib dose.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501066\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tasigna</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6860243\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tasigna</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501062\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, BCR-ABL Tyrosine Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501140\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> If clinically indicated, may be administered in combination with hematopoietic growth factors (eg, erythropoietin, filgrastim) and with hydroxyurea or anagrelide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute lymphoblastic leukemia (ALL), Philadelphia chromosome-positive (Ph+), newly diagnosed (off-label use):</b> Oral: 400 mg twice daily starting on day 8 of induction chemotherapy (in combination with daunorubicin, vincristine, and prednisolone); continue up to the start of stem cell transplant conditioning or until the end of consolidation therapy. Patients who completed 5 cycles of consolidation treatment received 2 years of nilotinib maintenance. Patients who underwent allogeneic stem cell transplant did not receive nilotinib after transplant (Kim 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ALL, Ph+, relapsed/refractory (off-label use):</b> Oral: 400 mg twice daily (Ottmann 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic myeloid leukemia (CML), Ph+, newly-diagnosed in chronic phase:</b> Oral: 300 mg twice daily (Kantarjian 2011b; Saglio 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Discontinuation of therapy (following a sustained molecular response [MR<sup>4.5</sup>]): </i>May consider nilotinib discontinuation in patients who have been treated with nilotinib for at least 3 years, maintained a molecular response of at least MR<sup>4.0 </sup>(corresponding to BCR-ABL/ABL &le;0.01% IS) for 1 year (prior to discontinuation), achieved an MR<sup>4.5 </sup>(corresponding to BCR-ABL/ABL &le;0.0032% IS) for the last assessment taken immediately prior to discontinuation, been confirmed to express the typical BCR-ABL transcripts (e13A2/b2a2 or e14a2/b3a2), no history of accelerated phase or blast crisis, and no history of prior attempts of treatment-free remission discontinuation that resulted in relapse.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Reinitiation of therapy: </i>Patients who lose major molecular response after nilotinib discontinuation must reinitiate treatment within 4 weeks at the dose used prior to discontinuation. Monitor BCR-ABL transcript levels monthly until major molecular response is re-established and every 12 weeks thereafter. BCR-ABL kinase domain mutation testing should be performed if major molecular response is not achieved after 3 months of therapy reinitiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CML, Ph+, resistant or intolerant in accelerated phase:</b> Oral: 400 mg twice daily (le Coutre 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CML, Ph+, resistant or intolerant in chronic phase:</b> Oral: 400 mg twice daily (Kantarjian 2007; Kantarjian 2011a)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Discontinuation of therapy (following a sustained molecular response [MR<sup>4.5</sup>]): </i>May consider nilotinib discontinuation in patients with CML in <b>chronic</b> phase (resistant or intolerant to prior imatinib therapy) who have been treated with nilotinib for at least 3 years, been treated with imatinib (only) prior to nilotinib treatment, achieved an MR<sup>4.5 </sup>(corresponding to BCR-ABL/ABL &le;0.0032% IS), achieved a sustained MR<sup>4.5</sup> for a minimum of 1 year immediately prior to discontinuation, been confirmed to express the typical BCR-ABL transcripts (e13A2/b2a2 or e14a2/b3a2), no history of accelerated phase or blast crisis, and no history of prior attempts of treatment-free remission discontinuation that resulted in relapse.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Reinitiation of therapy: </i>Patients with confirmed loss of MR<sup>4.0 </sup>(2 consecutive readings separated by at least 4 weeks showing loss of MR<sup>4.0</sup>) or loss of major molecular response after nilotinib discontinuation must reinitiate treatment within 4 weeks at the dose used prior to discontinuation. Monitor BCR-ABL transcript levels monthly until previous major molecular response or MR<sup>4.0</sup> is re-established and every 12 weeks thereafter. BCR-ABL kinase domain mutation testing should be performed if major molecular response is not achieved after 3 months of therapy reinitiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastrointestinal stromal tumor (GIST), refractory (off-label use):</b> Oral: 400 mg twice daily until disease progression or unacceptable toxicity (Reichardt 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> If a dose is missed, do not make up, resume with next scheduled dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant CYP3A4 inhibitors/inducers:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CYP3A4 inhibitors:</i> Avoid the concomitant use of a strong CYP3A4 inhibitor with nilotinib. If a strong CYP3A4 inhibitor is required, interruption of nilotinib treatment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If therapy cannot be interrupted and concurrent use with a strong CYP3A4 inhibitor cannot be avoided, consider reducing the nilotinib dose to 300 mg once daily in patients with resistant or intolerant Ph+ CML (chronic or accelerated phase) or to 200 mg once daily in newly diagnosed chronic phase Ph+ CML, with careful monitoring, especially of the QT interval. When a strong CYP3A4 inhibitor is discontinued, allow a washout period prior to adjusting nilotinib dose upward.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CYP3A4 inducers:</i> Avoid the concomitant use of a strong CYP3A4 inducer with nilotinib (based on pharmacokinetic parameters, an increased nilotinib dose is not likely to compensate for decreased exposure).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501141\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501142\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-top:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied in patients with serum creatinine &gt;1.5 times ULN); however, nilotinib and its metabolites have minimal renal excretion; dosage adjustments for renal dysfunction may not be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501143\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic impairment at treatment initiation:</b> <b>Note:</b> Consider alternative therapies first if possible; recommendations vary by indication</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase:</i> Mild to severe impairment (Child-Pugh class A, B, or C): Initial: 200 mg twice daily; may increase to 300 mg twice daily based on patient tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Resistant or intolerant Ph+ CML in chronic or accelerated phase:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate impairment (Child-Pugh class A or B): Initial: 300 mg twice daily; may increase to 400 mg twice daily based on patient tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment (Child-Pugh class C): Initial: 200 mg twice daily; may increase to 300 mg twice daily and then further increase to 400 mg twice daily based on patient tolerability</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatotoxicity during treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If bilirubin &ge; grade 3: Withhold treatment, monitor bilirubin, resume treatment at 400 mg once daily when bilirubin returns to &le; grade 1</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ALT or AST &ge; grade 3: Withhold treatment, monitor transaminases, resume treatment at 400 mg once daily when ALT or AST returns to &le; grade 1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501144\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic myeloid leukemia (Philadelphia chromosome-positive [Ph+]): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage adjustment for hematologic toxicity unrelated to underlying leukemia: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;1,000/mm<sup>3</sup> and/or platelets &lt;50,000/mm<sup>3</sup>: Withhold treatment, monitor blood counts</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If ANC &gt;1,000/mm<sup>3</sup> and platelets &gt;50,000/mm<sup>3</sup> within 2 weeks: Resume at prior dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If ANC &lt;1,000/mm<sup>3</sup> and/or platelets &lt;50,000/mm<sup>3</sup> for &gt;2 weeks: Reduce dose to 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage adjustment for nonhematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Amylase or lipase &ge; grade 3: Withhold treatment, monitor serum amylase or lipase, resume treatment at 400 mg once daily when lipase or amylase returns to &le; grade 1</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lipase increases in conjunction with abdominal symptoms: Withhold treatment and consider diagnostics to exclude pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Clinically-significant moderate or severe nonhematologic toxicity: Withhold treatment, upon resolution of toxicity, resume at 400 mg once daily; may escalate back to initial dose (300 mg twice daily or 400 mg twice daily depending on indication) if clinically appropriate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage adjustment for QT prolongation:</b> <b>Note:</b> Repeat ECG ~7 days after any dosage adjustment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">QTc &gt;480 msec: Withhold treatment, monitor and correct potassium and magnesium levels; review concurrent medications</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If QTcF returns to &lt;450 msec and to within 20 msec of baseline within 2 weeks: Resume at prior dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If QTcF returns to 450 to 480 msec after 2 weeks: Reduce dose to 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If QTcF &gt;480 msec after dosage reduction to 400 mg once daily: Discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia, Ph+, newly diagnosed (off-label use): </b>Temporarily reduce nilotinib dose to 400 mg once daily for &ge; grade 3 nonhematologic toxicity (resume when improved to grade 1); severe recurrent adverse events despite dose reduction may require permanent discontinuation (Kim 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501178\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tasigna: 150 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501060\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7885624\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s026lbl.pdf#page=32&amp;token=fXS1/5vMd1jEgQNSPC6TrGiRCs0CENIVkOMC97ozqUgUuQF9xQLUtk+3Ci6WbaTsif6P09pevt/me8x0Le79pstMEnJfGqdQgS7xsdLUpvQlwCnAw6YA8SSJMcpv2NzW&amp;TOPIC_ID=9448\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s026lbl.pdf#page=32</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501171\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer twice daily with doses ~12 hours apart. Administer on an empty stomach, at least 1 hour before or 2 hours after food. Capsules should be swallowed whole with water. If unable to swallow whole, may empty contents into 5 mL applesauce and administer within 15 minutes (do not save for later use).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104558\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501067\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic myelogenous leukemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in chronic phase.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of chronic- and accelerated-phase Philadelphia chromosome-positive CML in adults resistant or intolerant to prior therapy that included imatinib.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469152\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute lymphoblastic leukemia (ALL), Philadelphia chromosome-positive (Ph+); Gastrointestinal stromal tumor (GIST) (refractory)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501055\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nilotinib may be confused with bosutinib, dasatinib, imatinib, neratinib, nilutamide, nintedanib, niraparib, PONATinib, SUNItinib, vandetanib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501064\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (&le;15%), hypertension (10% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (20% to 35%), fatigue (21% to 32%), insomnia (7% to 12%), dizziness (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&le;38%), pruritus (20% to 32%), night sweats (12% to 27%), alopecia (11% to 13%), xeroderma (&gt;5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum glucose (50%), hyperglycemia (&le;50%), increased serum cholesterol (28%), increased serum triglycerides (12%), hypophosphatemia (&ge;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (22% to 37%), vomiting (13% to 29%), diarrhea (19% to 28%), increased serum lipase (28%), constipation (19% to 26%), upper abdominal pain (12% to 18%), abdominal pain (15% to 16%), decreased appetite (including anorexia; 15% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (1% to 15%; grades 3/4: 12% to 42%; median duration: 15 days), thrombocytopenia (18%; grades 3/4: 10% to 42%; median duration: 22 days), anemia (8%; grades 3/4: 4% to 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic: Increased serum ALT (10% to 72%), increased serum AST (10% to 47%), hyperbilirubinemia (&ge;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (16% to 26%), limb pain (15% to 20%), back pain (15% to 19%), myalgia (16% to 19%), weakness (14% to 16%), ostealgia (14% to 15%), muscle spasm (12% to 15%), musculoskeletal pain (11% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (17% to 27%), nasopharyngitis (&le;27%), upper respiratory tract infection (&le;17%), dyspnea (9% to 15%; exertional), oropharyngeal pain (&le;12%), flu-like symptoms (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (14% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Ischemic heart disease (5% to 9%), peripheral arterial disease (3% to 4%), cerebral ischemia (1% to 3%), pericardial effusion (&le;2%), angina pectoris, cardiac arrhythmia (including AV block, atrial fibrillation, bradycardia, cardiac flutter, extrasystoles, and tachycardia), chest discomfort, chest pain (including noncardiac), flushing, palpitations, prolonged Q-T interval on ECG</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, depression, flank pain, hypoesthesia, malaise, myasthenia, pain, paresthesia, peripheral neuropathy, vertigo, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris, dermatitis (including allergic and acneiform), eczema, erythema, folliculitis, hyperhidrosis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum albumin, diabetes mellitus, fluid retention, hypercalcemia, hypercholesterolemia, hyperkalemia, hyperlipidemia, hyperphosphatemia, hypertriglyceridemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, increased gamma-glutamyl transferase, increased HDL cholesterol, increased VLDL, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (4% to 10%), gastroenteritis (7%), gastrointestinal hemorrhage (&le;5%), abdominal distension, abdominal distress, dysgeusia, flatulence, increased serum amylase, pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Pollakiuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise, cutaneous papilloma, decreased hemoglobin, eosinophilia, febrile neutropenia, hemophthalmos, hemorrhage, leukopenia, lymphocytopenia, pancytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Ascites (&le;2%), hepatic insufficiency, increased serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Change in serum protein (decreased globulins)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase, neck pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eyelid edema (1%), conjunctivitis, eye pruritus, periorbital edema, xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pleural effusion (&le;2%), pulmonary edema (&le;2%), epistaxis, hoarseness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension, occlusive arterial disease (basilar, peripheral), pericarditis, reduced ejection fraction, shock (hemorrhagic), thrombosis, ventricular dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Amnesia, breast induration, cerebral edema, confusion, disorientation, dysesthesia, dysphoria, lethargy, restless leg syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermal ulcer, erythema multiforme, erythema nodosum, exfoliative dermatitis, furuncle, hyperkeratosis, palmar-plantar erythrodysesthesia, psoriasis, skin atrophy, skin blister, skin discoloration, skin hyperpigmentation, skin hypertrophy, skin photosensitivity, tinea pedis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Altered hormone level (insulin C-peptide decreased), hypermenorrhea, hyperparathyroidism (secondary), hyperuricemia, hypoglycemia, thyroiditis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Cholestasis, enterocolitis, gastric ulcer (perforation possible), gingivitis, hematemesis, hemorrhoids, hiatal hernia, intestinal obstruction, oral lesion (papilloma), rectal hemorrhage, ulcerative esophagitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria, urinary incontinence, urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Increased parathyroid hormone, leukocytosis, paraproteinemia, petechiae, retroperitoneal hemorrhage, thrombocythemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatomegaly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess, anal abscess, reactivation of HBV, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local swelling (nipple), localized edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; Skeletal: Arthritis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blepharitis, diplopia, eye pain, optic neuritis, papilledema, photophobia, retinopathy (central serous chorioretinopathy), swelling of eye</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Auditory impairment, otalgia, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pulmonary hypertension, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Benign nodule (sebaceous hyperplasia), cyst (dermal), troponin increased</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Allergic skin reaction, arteriosclerosis, ascorbic acid deficiency (Oak 2016), blurred vision, bronchitis, candidiasis, cardiac failure, cardiomegaly, cerebral infarction, chills, conjunctival hemorrhage, coronary artery disease, cyanosis, decreased visual acuity, dehydration, disturbance in attention, dysuria, ecchymoses, erectile dysfunction, esophageal pain, exfoliation of skin, eye irritation, facial edema, gastritis, gastroesophageal reflux disease, gout, gynecomastia, heart murmur, hematoma, hepatitis, hepatotoxicity, herpes simplex infection, hyperemia (scleral, conjunctival, ocular), hyperesthesia, hypertensive crisis, hyperthyroidism, hypothyroidism, increased appetite, increased blood urea nitrogen, increased lactate dehydrogenase, increased serum creatinine, intermittent claudication, interstitial pulmonary disease, intracranial hemorrhage, jaundice, joint swelling, lack of concentration, local alterations in temperature sensations, local discomfort (sensitive teeth), loss of consciousness, mastalgia, melena, mesenteric artery occlusion, migraine, myocardial infarction, nocturia, nonhemorrhagic stroke, occlusive arterial disease (coronary), oral mucosa ulcer, pharyngolaryngeal pain, photopsia, pleurisy, pleuritic chest pain, pneumonia, sinusitis, skin pain, stiffness, stomatitis, syncope, throat irritation, transient ischemic attacks, tremor, tumor lysis syndrome, urinary tract infection, urinary urgency, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501084\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypokalemia, hypomagnesemia, or long QT syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to nilotinib or any component of the formulation; persistent QTc &gt;480 msec</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501085\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Reversible myelosuppression, including grades 3 and 4 thrombocytopenia, neutropenia, and anemia may occur; may require dose reductions and/or treatment delay. Monitor blood counts every 2 weeks for the first 2 months, then monthly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular: Cardiovascular events such as ischemic heart disease-related events, arterial vascular occlusive events, peripheral arterial occlusive disease, and ischemic cerebrovascular accident have been reported. Use caution in patients with preexisting risk factors, and monitor for new or worsening symptoms suggestive of cardiovascular events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Electrolyte abnormalities may occur during treatment, including hypophosphatemia, hyper-/hypokalemia, hypocalcemia, and hyponatremia. Correct electrolyte abnormalities prior to treatment initiation; monitor periodically.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: Fluid retention, including pleural and pericardial effusions, ascites, and pulmonary edema were reported; may be severe. Monitor closely for signs/symptoms of fluid retention (eg, rapid weight gain or swelling) and for symptoms of respiratory or cardiac distress (eg, shortness of breath). Evaluate promptly and manage as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Serious hemorrhagic events (including fatal events) have occurred in chronic myelogenous leukemia (CML) patients treated with nilotinib. In a clinical study comparing nilotinib and imatinib in the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase CML, hemorrhagic events (eg, GI hemorrhage, including grade 3 or 4 events) occurred more frequently in the nilotinib arm. Monitor for signs/symptoms of bleeding and manage as clinically appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Nilotinib may cause hepatotoxicity, including dose-limiting elevations in bilirubin, transaminases, and alkaline phosphatase; monitor liver function monthly or as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation/sudden death: <b>[US Boxed Warning]: May prolong the QT interval; sudden deaths have been reported. Use in patients with hypokalemia, hypomagnesemia, or long QT syndrome is contraindicated. Correct hypomagnesemia and hypokalemia prior to initiating therapy; monitor electrolytes periodically. Monitor ECG and QTc (baseline, at 7 days, with dose change, and periodically). Avoid the use of QT-prolonging agents and strong CYP3A4 inhibitors;</b> also avoid concurrent use with antiarrhythmics; may increase the risk of potentially-fatal arrhythmias. The sudden deaths reported appear to be related to dose-dependent ventricular repolarization abnormalities. Prolonged QT interval may result in torsade de pointes, which may cause syncope, seizure, and/or death. Patients with uncontrolled or significant cardiovascular disease were excluded from studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS) has been reported in patients with resistant or intolerant CML; the majority of cases had malignant disease progression, high WBC counts, and/or dehydration. Maintain adequate hydration and treat high uric acid levels prior to nilotinib initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrectomy: Consider alternative therapy or a dosage increase (with more frequent monitoring) in patients with total gastrectomy (nilotinib exposure is reduced).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Dosage reduction is recommended in patients with hepatic impairment, along with close monitoring of QT interval. Nilotinib metabolism is primarily hepatic; exposure is increased in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Use with caution in patients with a history of pancreatitis, may cause dose-limiting elevations of serum lipase and amylase; monitor. In patients with abdominal symptoms in conjunction with lipase increases, withhold treatment and consider diagnostics to exclude pancreatitis. Monitor serum lipase levels monthly or as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.<b> [US Boxed Warning]: Avoid concurrent use with medications known to prolong the QT interval and with strong CYP3A4 inhibitors. </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polymorphisms: UGT1A1 polymorphisms may be a risk factor for increased toxicity (eg, hyperbilirubinemia) (Shibata 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Capsules contain lactose; do not use with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption syndromes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate administration: <b>[US Boxed Warning]: Administer on an empty stomach, at least 1 hour before and 2 hours after food.</b> Food increased the bioavailability/serum levels which may then prolong QTc. Nilotinib solubility is decreased at higher pH; concurrent use with proton pump inhibitors is not recommended. If necessary, H<sub>2</sub>-receptor blockers may be administered ~10 hours before and 2 hours after a nilotinib dose. Antacids (eg, aluminum hydroxide, magnesium hydroxide, simethicone) may be administered ~2 hours before or 2 hours after nilotinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; BCR-ABL transcript monitoring: Monitor BCR-ABL transcript levels in patients eligible for treatment discontinuation using an authorized test validated to measure molecular response levels with a sensitivity of at least MR<sup>4.5</sup> (BCR-ABL/ABL &le;0.0032% IS). Information on authorized tests for detection and quantitation of BCR-ABL transcripts is available at <a target=\"_blank\" href=\"http://www.fda.gov/CompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc+kYYsON95PtA1EteUbfjUoJYJ+uveJw2PtFUTXMkK&amp;TOPIC_ID=9448\" target=\"_blank\">http://www.fda.gov/CompanionDiagnostics</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501117\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak), CYP3A4 (moderate), UGT1A1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501116\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9448&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Nilotinib. Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor.  The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving moderate inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose to 20 mg daily.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Substrates (High risk with Inducers): Nilotinib may decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Nilotinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Nilotinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); Praziquantel; Trabectedin; Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan.  Management: The use of eletriptan within 72 hours of a moderate CYP3A4 inhibitor should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations vary by indication and international labeling. See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Nilotinib. Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 140 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: UGT1A1 Inhibitors may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. UGT1A1 Inhibitors may increase the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.  No dose adjustment is needed when using ivacaftor/lumacaftor with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: Nilotinib may increase the serum concentration of Lomitapide.  Management: Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half with concurrent nilotinib; the lomitapide dose may then be increased to a max adult dose of 30 mg/day (patients on lomitapide 5 mg/day may continue that dose).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: Lurasidone US labeling recommends reducing lurasidone dose by half with a moderate CYP3A4 inhibitor. Some non-US labeling recommends initiating lurasidone at 20 mg/day and limiting dose to 40 mg/day; avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Nilotinib. Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of Nilotinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Nilotinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor.  Management: When combined with moderate CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be given in the morning, every other day. Ivacaftor (150 mg) alone should be given in the evening, every other day, on alternate days from tezacaftor/ivacaftor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combination should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.  Management: The starting adult dose of zopiclone should not exceed 3.75 mg if combined with a moderate CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501120\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may result in increased concentrations of nilotinib and potentiate QT prolongation. Management: Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501070\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on data from animal reproduction studies and the mechanism of action, nilotinib may cause fetal harm if administered during pregnancy. Verify pregnancy status in females of reproductive potential prior to initiating therapy. Women of reproductive potential should be advised to use effective contraception during treatment and for at least 14 days after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501083\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if nilotinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for at least 14 days after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501123\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The bioavailability of nilotinib is increased with food. Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501173\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Philadelphia chromosome status (prior to treatment); CBC with differential (every 2 weeks for first 2 months, then monthly); electrolytes (including potassium, calcium, and magnesium; baseline and periodic); lipid profile and glucose (baseline and periodically during the first year, then at least yearly), hepatic function (ALT/AST, bilirubin, alkaline phosphatase; baseline and monthly or as clinically indicated); serum lipase/amylase (baseline and monthly or as clinically indicated), uric acid (baseline); bone marrow assessments; pregnancy test (in females of reproductive potential; prior to initiating therapy); ECG and QTc (baseline, 7 days after treatment initiation or dosage adjustments, and periodically thereafter); signs/symptoms of cardiovascular events, hemorrhage, or fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In patients who discontinue nilotinib after a sustained molecular response (MR<sup>4.5</sup>), monitor BCR-ABL transcript levels and CBC with differential monthly for 1 year, then every 6 weeks for the second year, and every 12 weeks thereafter. Upon the loss of MR<sup>4.0 </sup>(corresponding to BCR-ABL/ABL &le;0.01% IS) during the treatment-free phase, monitor BCR-ABL transcript levels every 2 weeks until the BCR-ABL levels remain lower than major molecular response (MMR, corresponding to MR<sup>3.0</sup> or BCR-ABL/ABL &le;0.1% IS) for 4 consecutive measurements; patients can then proceed to the original monitoring schedule. In patients who have reinitiated nilotinib after loss of molecular response, monitor CBC and BCR-ABL transcript levels every 4 weeks until a major molecular response (MR<sup>4.0</sup>) is re-established, and then every 12 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Thyroid function testing (Hamnvik 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preexisting levothyroxine therapy: Obtain baseline thyroid-stimulating hormone (TSH) levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Without preexisting thyroid hormone replacement: TSH at baseline, then monthly for 4 months, then every 2 to 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501169\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nilotinib is a selective tyrosine kinase inhibitor that targets BCR-ABL kinase, c-KIT and platelet derived growth factor receptor (PDGFR); it does not have activity against the SRC family. Nilotinib inhibits BCR-ABL mediated proliferation of leukemic cell lines by binding to the ATP-binding site of BCR-ABL and inhibiting tyrosine kinase activity. Nilotinib has activity in imatinib-resistant BCR-ABL kinase mutations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5501131\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~98%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; oxidation and hydroxylation, via CYP3A4 to primarily inactive metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Capsule: ~50% (when compared to oral solution with pH of 1.2 to 1.3); two 200 mg capsules sprinkled on applesauce was determined to be bioequivalent to two 200 mg intact capsules; bioavailability is increased 82% when administered 30 minutes after a high-fat meal </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~15 to 17 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (93%; 69% as parent drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321790\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tasigna Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (28): $3,820.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (28): $3,820.34</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038900\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Tasigna (AE, AR, AT, AU, BB, BE, BH, BR, CH, CL, CN, CO, CU, CY, CZ, DE, DK, EC, EE, ES, FR, GB, GR, HK, HN, HR, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MY, NL, NO, NZ, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VN, ZW);</li>\n      <li>Tasyhna (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Andolina JR, Neudorf SM, and Corey SJ, &ldquo;How I Treat: Childhood CML,&rdquo; <i>Blood</i>, 2011, 119(8):1821-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/22210880/pubmed\" target=\"_blank\" id=\"22210880\">22210880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baccarani M, Cortes J, Pane F, et al, &ldquo;Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet,&rdquo; <i>J Clin Oncol</i>, 2009, 27(35):6041-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/19884523/pubmed\" target=\"_blank\" id=\"19884523\">19884523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Branford S, Kim DW, Soverini S, et al, &ldquo;Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib,&rdquo; <i>J Clin Oncol</i>, 2012, 30(35):4323-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/23109697/pubmed\" target=\"_blank\" id=\"23109697\">23109697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cornelison M, Jabbour EJ, and Welch MA, &ldquo;Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients With Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner,&rdquo; <i>J Support Oncol</i>, 2012, 10(1):14-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/22244674/pubmed\" target=\"_blank\" id=\"22244674\">22244674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes JE, Hochhaus A, le Coutre PD, et al, &ldquo;Minimal Cross-Intolerance With Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase Who are Intolerant to Imatinib,&rdquo; <i>Blood</i>, 2011, 117(21):5600-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/21467546/pubmed\" target=\"_blank\" id=\"21467546\">21467546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al, &ldquo;Nilotinib in Imatinib-Resistant or Imatinib-Intolerant Patients With Chronic Myeloid Leukemia in Chronic Phase: 48-Month Follow-Up Results of a Phase II Study,&rdquo; <i>Leukemia</i>, 2013, 27(1):107-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/22763385/pubmed\" target=\"_blank\" id=\"22763385\">22763385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochhaus A, Saglio G, Larson RA, et al, &ldquo;Nilotinib is Associated With a Reduced Incidence of BCR-ABL Mutations vs Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase,&rdquo; <i>Blood</i>, 2013, 121(18):3703-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/23502220/pubmed\" target=\"_blank\" id=\"23502220\">23502220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jabbour E, Kantarjian HM, O'Brien S, et al, &ldquo;Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What is the Optimal Response?&rdquo; <i>J Clin Oncol</i>, 2011, 29(32):4260-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/21990394/pubmed\" target=\"_blank\" id=\"21990394\">21990394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian HM, Giles FJ, Bhalla KN, et al, &ldquo;Nilotinib is Effective in Patients With Chronic Myeloid Leukemia in Chronic Phase After Imatinib Resistance or Intolerance: 24-Month Follow-Up Results,&rdquo; <i>Blood</i>, 2011a, 117(4):1141-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/21098399/pubmed\" target=\"_blank\" id=\"21098399\">21098399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian HM, Giles F, Gattermann N, et al, &ldquo;Nilotinib (Formerly AMN107), a Highly Selective Bcr-Abl Tyrosine Kinase Inhibitor, is Effective in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase Following Imatinib Resistance and Intolerance,&rdquo; <i>Blood</i>, 2007, 110(10):3540-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/17715389/pubmed\" target=\"_blank\" id=\"17715389\">17715389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian H, Giles F, Wunderle L, et al, &ldquo;Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL,&rdquo; <i>N Engl J Med</i>, 2006, 354(24):2542-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/16775235/pubmed\" target=\"_blank\" id=\"16775235\">16775235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian HM, Hochhaus A, Saglio G, et al, &ldquo;Nilotinib Versus Imatinib for the Treatment of Patients With Newly Diagnosed Chronic Phase, Philadelphia Chromosome-Positive, Chronic Myeloid Leukaemia: 24-Month Minimum Follow-Up of the Phase 3 Randomised ENESTnd Trial,&rdquo; <i>Lancet Oncol</i>, 2011b, 12(9):841-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/21856226/pubmed\" target=\"_blank\" id=\"21856226\">21856226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26065651\"></a>Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood.</i> 2015;126(6):746-756. doi: 10.1182/blood-2015-03-636548.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/26065651/pubmed\" target=\"_blank\" id=\"26065651\">26065651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kl&uuml;mpen HJ, Samer CF, Mathijssen RH, et al, &ldquo;Moving Towards Dose Individualization of Tyrosine Kinase Inhibitors,&rdquo; <i>Cancer Treat Rev</i>, 2011, 37(4):251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/20833478/pubmed\" target=\"_blank\" id=\"20833478\">20833478</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Hochhaus A, Hughes TP, et al, &ldquo;Nilotinib vs Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 3-Year Follow-Up,&rdquo; <i>Leukemia</i>, 2012, 26(10):2197-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/22699418/pubmed\" target=\"_blank\" id=\"22699418\">22699418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22076466\"></a>le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.<i> Leukemia.</i> 2012;26(6):1189-1194. doi: 10.1038/leu.2011.323.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/22076466/pubmed\" target=\"_blank\" id=\"22076466\">22076466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montemurro M, Sch&ouml;ffski P, Reichardt P, et al, &ldquo;Nilotinib in the Treatment of Advanced Gastrointestinal Stromal Tumours Resistant to Both Imatinib and Sunitinib,&rdquo; <i>Eur J Cancer</i>, 2009, 45(13):2293-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/19467857/pubmed\" target=\"_blank\" id=\"19467857\">19467857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolini FE, Turkina A, Shen ZX, et al, &ldquo;Expanding Nilotinib Access in Clinical Trials (ENACT): An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in the Chronic Phase,&rdquo; <i>Cancer</i>, 2012, 118(1):118-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/21732337/pubmed\" target=\"_blank\" id=\"21732337\">21732337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oak AS, Jaleel T, Fening K, Pavlidakey PG, Sami N. A case of scurvy associated with nilotinib [published online April 28, 2016]. <i>J Cutan Pathol</i>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23138184\"></a>Ottmann OG, Larson RA, Kantarjian HM, et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia.</i> 2013;27(6):1411-1413. doi: 10.1038/leu.2012.324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/23138184/pubmed\" target=\"_blank\" id=\"23138184\">23138184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27932374\"></a>Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.<i> Blood.</i> 2017;129(7):846-854. doi: 10.1182/blood-2016-09-742205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/27932374/pubmed\" target=\"_blank\" id=\"27932374\">27932374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22357255\"></a>Reichardt P, Blay JY, Gelderblom H, et al, &ldquo;Phase III Study of Nilotinib versus Best Supportive Care With or Without a TKI In Patients With Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and Sunitinib,&rdquo; <i>Ann Oncol</i>, 2012, 23(7):1680-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/22357255/pubmed\" target=\"_blank\" id=\"22357255\">22357255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saglio G, Kim DW, Issaragrisil S, et al, &ldquo;Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia,&rdquo; <i>N Engl J Med</i>, 2010, 362(24):2251-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/20525993/pubmed\" target=\"_blank\" id=\"20525993\">20525993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shibata T, Minami Y, Mitsuma A, et al, &ldquo;Association Between Severe Toxicity of Nilotinib and UGT1A1 Polymorphismsin Japanese Patients With Chronic Myelogenous Leukemia,&rdquo; <i>Int J Clin Oncol</i>, 2013 [epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/23609856/pubmed\" target=\"_blank\" id=\"23609856\">23609856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tasigna (nilotinib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weisberg E, Manley P, Mestan J, et al, &ldquo;AMN107 (Nilotinib): A Novel and Selective Inhibitor of BCR-ABL,&rdquo; <i>Br J Cancer</i>, 2006, 94(12):1765-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/16721371/pubmed\" target=\"_blank\" id=\"16721371\">16721371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yin OQ, B&eacute;doucha V, McCulloch T, et al, &ldquo;Effects of Famotidine or an Antacid Preparation on the Pharmacokinetics of Nilotinib in Healthy Volunteers,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2013, 71(1):219-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nilotinib-drug-information/abstract-text/23070146/pubmed\" target=\"_blank\" id=\"23070146\">23070146</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9448 Version 197.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50889225\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709171\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F5501066\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6860243\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5501062\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5501140\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5501141\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F5501142\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5501143\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F5501144\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5501178\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5501060\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7885624\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5501171\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104558\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5501067\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469152\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5501055\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5501064\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5501084\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5501085\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F5501117\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5501116\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F5501120\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5501070\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5501083\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F5501123\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5501173\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5501169\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5501131\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321790\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038900\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9448|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nilotinib-patient-drug-information\" class=\"drug drug_patient\">Nilotinib: Patient drug information \t</a></li></ul></div></div>","javascript":null}